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Summary 15 
Atovaquone is used as a fixed dose combination with proguanil (MalaroneTM), either 16 
for treating children and adults with uncomplicated malaria or as a chemoprophylaxis 17 
for preventing malaria in travellers. Indeed in the US, between 2009-2011, MalaroneTM 18 
prescriptions accounted for 70% of all antimalarial pre-travel prescriptions. In 2013 19 
the patent for MalaroneTM will expire, potentially resulting in a wave of low-cost 20 
generics.  Furthermore, the malaria scientific community has a number of antimalarial 21 
quinolones, with a related pharmacophore to atovaquone, at various stages of pre-22 
clinical development. With this in mind, it is timely here to review the current 23 
knowledge of atovaquone, with the purpose of aiding decision making of clinicians 24 
and drug developers involved in the future use of atovaquone generics or atovaquone 25 
derivatives. 26 
 27 
Introduction  28 
Atovaquone is the end product of half a century of research by many groups who researched 29 
the antiparasitic properties of numerous structurally related compounds.1-6 Currently 30 
Atovaquone is used as a fixed dose combination with proguanil (MalaroneTM), for the 31 
treatment of children and adults with uncomplicated malaria or as a chemoprophylactic 32 
agent for preventing malaria in travellers.7, 8 Between 2009 and 2011 in the US MalaroneTM 33 
accounted for 70% of all antimalarial pre-travel prescriptions.9  34 
The development of atovaquone as an antimalarial drug began over 50 years ago when the 35 
outbreak of World War 2 caused substantial shortages in the supply of quinine.10 Intense 36 
  
efforts in America led to thousands of structurally diverse compounds being investigated, 37 
several of which were hydroxynaphthoquinones. Modest antimalarial activity when 38 
administered to ducks infected with Plasmodium lophurae resulted in a robust lead 39 
optimisation programme generating more than 300 quinones, some of which demonstrated 40 
greater activity than quinine in the duck assay. However, when administered to malaria 41 
patients these compounds were devoid of any activity due to poor absorption and rapid 42 
metabolism.11, 12 Attempts to solve these problems and produce an orally active quinine were 43 
unsuccessful both then and when the problem was re-visited in the 1960s.13 Research in the 44 
1960s did however lead the development of Lapinone (1), which was given intravenously 45 
and had activity against Plasmodium vivax (Figure 1).14 46 
 47 
The use of quinones as antimalarial agents was then reinvestigated in the 1980s by a group 48 
at the Wellcome Research Laboratories.  More meaningful studies could be carried out at 49 
this time due to the development of test systems using the human parasite Plasmodium 50 
falciparum in vitro or in Aotus monkeys. The aim of this study was to design a quinone with 51 
good antimalarial activity against P. falciparum combined with good metabolic stability in 52 
humans. Several 2-cyclohexyl-3-hydroxy-1,4-naphthoquinone analogues (2 and 3) were 53 
synthesised with the metabolically labile 4’ position of the cyclohexyl ring substituted with a 54 
range of groups.15, 16 Several of these quinones demonstrated a potency of ~1 nM towards 55 
P. falciparum in vitro but only atovaquone (4) was inert to human liver microsomes.17, 18 The 56 
trans isomer of atovaquone is substantially more potent than corresponding cis isomer. The 57 
chemical synthesis of atovaquone was originally disclosed in 1991 in US patent 58 
No.4981874. This route gave a poor yield of 4% atovaquone calculated from only the last 59 
two steps (Figure 2A).19 60 
 61 
Williams and Clark then published a variant of this methodology (Figure 2B) in which oxalate 62 
(11) was used to produce racemic compound (9) in 43% yield and the ester by-product (12) 63 
in 38% yield.20 Conversion to atovaquone was then achieved as described in Figure 2A. The 64 
disadvantages of this process are the column chromatography required to separate (9) from 65 
(12) and the same poor yield problem will still prevail in the final two steps.  66 
 67 
Both processes described so far also involve the use of silver nitrate, a heavy metal which 68 
can be difficult to remove and whose use is tightly regulated. The recently patented (WO 69 
2010/001379) synthesis seen in Figure 2C offers an improved synthesis of atovaquone as it 70 
is higher yielding and doesn’t involve the use of heavy metals.21 71 
 72 
  
A common problem with all the routes so far is that large amounts of the potentially useful, 73 
yet significantly less potent  cis isomer of atovaquone are disregarded as only the trans 74 
isomer is required. There are two literature procedures that address this problem. Reacting 75 
the cis isomer of atovaquone, atovaquone intermediates or isomeric mixtures thereof with a 76 
strong acid results in a clean epimerization to the corresponding trans isomer and thus to 77 
high yields of trans atovaquone.22 Heating the cis isomer at reflux in organic solvent also 78 
carries out this transformation.23 79 
 80 
With the patent relating to Malarone due to expire in 2013 the synthesis of atovaquone will 81 
be exploited to its full potential as generic versions of the drug are likely to become common 82 
place. This will in turn have a marked effect on the cost of goods as currently the high cost of 83 
atovaquone is frequently prohibitive in its use by the endemic population within countries 84 
affected by malaria. Increased availability and use of the drug will also have an effect on the 85 
clinical efficacy of atovaquone and factors such as access, sustainability, and resistance 86 
need to be considered.24 Furthermore, the malaria scientific community has a number of 87 
antimalarial quinolones, with a related pharmacophore to atovaquone, at various stages of 88 
pre-clinical development.25-30 89 
 90 
Pharmacodynamics 91 
Mode of Action.  Atovaquone is a competitive inhibitor of ubiquinol, specifically inhibiting the 92 
mitochondrial electron transport chain at the bc1 complex.31 Inhibition of bc1 activity results in 93 
a loss of mitochondrial function.32, 33 During the intra-erythrocytic stage of infection, a key 94 
role of the parasite mitochondrion is to provide orotate for pyrimidine biosynthesis through 95 
the activity of dihydroorotate dehydrogenase (DHODH). Consistent with this, inhibition of the 96 
bc1 complex by atovaquone affects the concentrations of metabolites in the pyrimidine 97 
biosynthetic pathway.34, 35 Indeed, transgenic P. falciparum parasites expressing ubiquinone-98 
independent yeast DHODH have been shown to display an atovaquone-resistant 99 
phenotype.36 In addition, a recent study suggests that a further cellular consequence of 100 
mitochondrial inhibition by atovaquone is the inhibition of purine biosynthesis.37 Blood stage 101 
parasite death as a result of atovaquone is relatively slow compared to other antimalarials 102 
such as artemisinin and chloroquine.25, 38 This feature appears to be consistent with other 103 
mitochondrial-acting antimalarials and is possibly due to the drug acting only on late 104 
trophozoites and not on the earlier “ring” stages.25 Atovaquone is however active against 105 
liver stages, resulting in its utility as a prophylaxis drug, however it is not believed to be 106 
active against “dormant” hypnozoites.8, 39 107 
 108 
  
Mechanism of Parasite Resistance to Atovaquone/MalaroneTM.  Although the crystal 109 
structure of the P. falciparum cytochrome bc1 complex is not available, details of atovaquone 110 
binding to cytochrome b have been elucidated based on studies performed on model 111 
organisms and molecular modelling.  These studies, that include Electron Paramagnetic 112 
Resonance spectroscopy of the Rieske [2Fe-2S] cluster, site-directed mutagenesis of model 113 
organism cytochrome b, and gene sequencing of atovaquone-resistant Plasmodium species, 114 
demonstrate that atovaquone is most likely a competitive inhibitor of the parasite's 115 
cytochrome b quinol oxidation (Qo) site (Figure 3).28, 40 116 
 117 
MalaroneTM drug failure has been associated with a mis-sense point mutation at position 268 118 
in cytochrome b, exchanging tyrosine for serine (Y268S) or, less frequently, asparagine 119 
(Y268N).41-45 Position 268 in cytochrome b is highly conserved across all phyla and is 120 
located within the “ef” helix component of the Qo site which is putatively involved in ubiquinol 121 
binding. The resultant atovaquone-resistant growth IC50 phenotype of these mutants is some 122 
1000-fold higher than susceptible strains, however this is accompanied by a ~40 % 123 
reduction in the Vmax of the bc1 complex, suggestive of a significant fitness cost to the 124 
parasite.46 125 
 126 
It is well documented that atovaquone monotherapy gives rise to de novo resistance very 127 
rapidly.47, 48 However, the underlying reason for this phenomenon has not been determined 128 
and, as discussed in the next section, may be partially explained by pharmacokinetic 129 
considerations (related to the physicochemical properties of atovaquone) as well as hitherto 130 
untested considerations related to the molecular target such as for example the effect of an 131 
increased mutation rate of mitochondrially-encoded genes such as cytochrome b compared 132 
to nuclear encoded genes.49 Furthermore, it has been reported that an in vitro atovaquone 133 
resistant parasite line has been generated in the laboratory possessing wild-type cyt b.50 The 134 
mechanism underpinning the parasite’s atovaquone resistant phenotype in this strain 135 
remains to be elucidated. 136 
 137 
Pharmacokinetics 138 
The pharmacokinetic parameters of atovaquone in the currently utilised formulation 139 
(Malarone™, 250 mg atovaquone + 100 mg proguanil) have been determined (Figure 4).51 140 
Median atovaquone plasma AUC (h.µM), t1/2 (h), Cmax (µM) and tmax (h) were 295, 87.2, 3.74, 141 
3.25, respectively, following single-dose and 254, 55.9, 13.8 and 4.00, respectively, upon 142 
reaching steady-state. The similar AUC values observed between single-dose and steady-143 
state dosing suggests no unexpected accumulation of atovaquone following repeated 144 
  
administration, although this may be due to saturation of plasma atovaquone concentrations 145 
and an increase in atovaquone concentrations in tissues cannot be ruled out.  146 
 147 
Atovaquone IC50 against susceptible malaria in vitro is very low, ranging from 1 to ~3.5 nM. 148 
31, 52, 53 This has resulted in the belief that atovaquone plasma concentrations (around 1-10 149 
µM, see Figure 4) are sufficient to produce total suppression of malaria. However, 150 
atovaquone shows extremely high levels of plasma protein binding (>99.5%) and therefore 151 
the concentration of un-bound atovaquone is likely to be significantly lower.54 Extrapolations 152 
of Pharmacokinetic-Pharmacodynamic dynamics using in vitro data should therefore be 153 
treated with caution. 154 
 155 
At present, there are no established minimum effective plasma concentrations of 156 
atovaquone for malaria prophylaxis. However, a clear correlation between atovaquone 157 
steady-state plasma concentration and treatment success has been established in 158 
Pneumocystis pneumonia in patients with AIDS.55 Atovaquone plasma concentrations of 10 159 
to <15 µg / mL and 15 to <20 µg / mL resulted in 79% and 95% treatment success, 160 
respectively. Furthermore, there have been case reports of atovaquone treatment failure in 161 
antimalarial therapy that were not explained by drug resistance mutations, and patients with 162 
body weight >100 kg have a marked increased chance of treatment failure compared to 163 
<100 kg patients, both of which suggest drug concentration may be a factor in determining 164 
treatment failure.42, 56, 57 The prediction of atovaquone therapy failure and resistance 165 
selection using drug concentration parameters has the potential to improve current patient 166 
therapy and an investigation determining a PK-PD relationship is warranted. 167 
 168 
Absorption.  Absorption of atovaquone shows dose-limitation, with maximum absorption 169 
observed using 750 mg tablets.58 Poor drug solubility was suggested as the cause of this 170 
limit to absorption, and this led to the development of an atovaquone liquid suspension 171 
formulation, which showed improved Pneumocystis pneumonia treatment success compared 172 
to the tablet formation.59 173 
 174 
The bioavailability of 750 mg atovaquone when taken with food was 23% in HIV-infected 175 
patients.60 Combining data from six clinical trials, the inter-patient variability of atovaquone 176 
bioavailability is substantial and has been determined at 107%, which is likely due to the 177 
drug’s low solubility and the effects of food.60-62 178 
 179 
  
The oral absorption of atovaquone increased when taken with a high fat meal (2 slices of 180 
toast with 56 g butter, with 3.9-fold exposure compared to fasted), whereas a minimal-fat 181 
meal (2 slices of toast) had minimal impact on absorption.62 Consequently, it is 182 
recommended that atovaquone be taken with a high-fat meal. However, a recent in vitro 183 
study showed that atovaquone IC50 increased 20-fold when serum used in the assay was 184 
taken from a subject recently given a high-fat meal, compared to serum from a fasted 185 
subject (0.5 ng / mL to 12 ng / mL, p < 0.01).63 A correlation between high serum triglyceride 186 
concentrations and high atovaquone IC50 was observed, suggesting reduced free (unbound) 187 
atovaquone concentrations due to increased drug-fat binding. The clinical relevance of this 188 
finding is unknown, but the impact to atovaquone PK is likely to be transient and is unlikely 189 
to outweigh the benefit of increased atovaquone absorption. 190 
 191 
Dissolution of atovaquone tablets increases in the presence of milk, and therefore the 192 
presence of milk in meals may increase atovaquone bioavailability in patients.61 This may 193 
provide an alternative strategy to high-fat meals when aiming to maximise the bioavailability 194 
of atovaquone, although this has not been shown clinically. 195 
 196 
Distribution.  Atovaquone is highly bound to plasma protein (>99.5%) and shows high affinity 197 
for human serum albumin, although the low drug clearance rate suggests that atovaquone 198 
may also accumulate in tissues, where it is protected from biliary clearance.54 In a study of 199 
atovaquone population pharmacokinetics, the volume of distribution of atovaquone was 7.98 200 
L / kg, although individual values were markedly linked to body weight; volume of distribution 201 
shows a linear increase with increased patient body weight.60 202 
 203 
Metabolism.  Under normal conditions, there is no evidence that atovaquone is significantly 204 
metabolised in humans, or that metabolism is required for drug elimination. It may be 205 
possible that certain enzymes could be induced and therefore lead to increased atovaquone 206 
biotransformation, but this has not been demonstrated. 207 
 208 
Elimination.  Atovaquone pharmacokinetics is characterised by an extremely long elimination 209 
half life of around 50 to 84 hours.58, 62, 64 Elimination is primarily via the liver, with almost 210 
undetectable amounts (<0.6%) of drug being eliminated via the kidney.65 Over 90% of drug 211 
excreted in bile was in the parent form. Elimination of atovaquone is complicated by the 212 
possibility of enterohepatic recirculation of drug, which may help explain atovaquone 213 
pharmacokinetic profiles where reduction and then increases in drug concentration are seen 214 
with time. 215 
  
 216 
In a study of atovaquone population pharmacokinetics, the oral clearance of atovaquone 217 
was increased in patients with higher body weight, with 60% increased clearance seen in an 218 
80 kg patient compared to a 40 kg patient.60 In the same study, the average oral clearance 219 
of atovaquone was higher in Oriental (8.49 L / h) and Malay (9.13 L / h) subjects compared 220 
to white (1-7.6 L / h) subjects.60 221 
 222 
Drug interactions 223 
Atovaquone is highly bound to plasma protein (>99.5%) and shows high affinity for human 224 
serum albumin.54 Furthermore, the half life of atovaquone is long, ranging around 50 to 84 225 
hours and the major limiting factor to atovaquone clearance is likely its plasma protein 226 
binding.58, 62, 64 This suggests that any drug which reduces atovaquone plasma protein 227 
binding may potentially alter atovaquone tissue distribution and/or clearance. However, the 228 
authors can find no published articles investigating the drug-mediated displacement of 229 
atovaquone from plasma protein and the clinical impact of these interactions, and this area 230 
requires further research. The interaction observed between atovaquone and antiretrovirals, 231 
where efavirenz, lopinavir and ritonavir (all highly protein-bound drugs) reduced atovaquone 232 
plasma concentrations in HIV-infected patients, may involve atovaquone plasma-protein 233 
displacement, although this was not demonstrated.66 This emphasises the importance of 234 
establishing the interactions between antimalarials, including atovaquone, and antiretrovirals. 235 
 236 
The potential for atovaquone to displace other protein-bound drugs has been investigated. A 237 
case study has recently been published which describes a potential interaction between the 238 
anticoagulant drug warfarin and atovaquone, where the author suggests that atovaquone 239 
caused an increase in free warfarin concentrations to super-therapeutic levels.67 A separate 240 
investigation found that atovaquone did not alter the pharmacokinetics of the antiepileptic 241 
drug phenytoin, another highly protein-bound drug which is susceptible to displacement 242 
interactions.68 The evidence that atovaquone can compete with other drugs for plasma 243 
protein binding is lacking, although further investigations are required to fully understand this 244 
potential factor in atovaquone pharmacokinetics. 245 
 246 
Atovaquone exposure is markedly decreased when taken concomitantly with the antibiotic 247 
drug rifampicin and therefore co-administration of atovaquone and rifampicin is not 248 
recommended.69 The mechanism behind this interaction is not fully understood, although the 249 
ability of rifampicin to induce activity of metabolism enzymes and drug transporters is 250 
assumed to be responsible. However, no metabolite of atovaquone has been identified in 251 
  
humans, and the impact of individual enzymes and transporters on atovaquone disposition is 252 
unclear. 253 
 254 
There is evidence that atovaquone can inhibit cytochrome P450 enzymes, although data has 255 
been generated in vitro and the relevance to clinical drug interactions is unknown. 256 
Atovaquone inhibited the metabolism of 50 µM 7-benzyloxy-4-(trifluoromethyl)-coumarin 257 
(BFC) by recombinant CYP3A4, with an IC50 of 4.7 µM.51 Similarly, sulfamethoxazole (SMX) 258 
metabolism by recombinant CYP2C9 was inhibited by atovaquone, with a Ki of 15 µM.70 259 
However, when atovaquone was pre-incubated with human serum and centrifuge-filtered to 260 
remove protein before use, no CYP2C9 inhibitory activity was observed. A recent case study 261 
described a HIV-infected female with a marked increase in plasma concentrations of 262 
antiretroviral drugs etravirine (+55%) and unboosted saquinavir (+274%) following 263 
atovaquone / proguanil prophylaxis.71 In the same study, raltegravir plasma concentrations 264 
were unchanged following atovaquone/proguanil prophylaxis. The evidence that 265 
atovaquone/proguanil prophylaxis increases exposure of etravirine and saquinavir (both 266 
cytochrome P450 substrates) but not raltegravir (no affinity for cytochrome P450 enzymes) 267 
suggests atovaquone, proguanil, or indeed both drugs, may be inhibiting cytochrome P450 268 
activity.72-74 269 
 270 
Co-administration of atovaquone and the nucleoside reverse transcriptase inhibitor 271 
zidovudine increased the exposure (33% increase in AUC0-8h, p < 0.05) and decreased the 272 
oral clearance (25% reduction, p < 0.05) of zidovudine in HIV-infected patients.75 273 
Furthermore, patients taking atovaquone showed a trend towards lower zidovudine-274 
glucuronide plasma concentrations (6% reduction in AUC0-8h, p < 0.1) and a significant 275 
decrease in the ratio between zidovudine-glucuronide and  plasma concentrations (30% 276 
reduction, p < 0.05). Atovaquone exposure was unchanged when co-administered with 277 
zidovudine.  278 
 279 
The atovaquone-mediated 33% increase in zidovudine exposure is in itself unlikely to cause 280 
increased hematologic toxicity, although caution is advised in patients taking additional 281 
drugs with similar toxicity profiles to zidovudine.75 Also, increased zidovudine plasma 282 
concentrations and reduced zidovudine glucuronidation may potentially lead to increased 283 
formation of the cytochrome P450-mediated zidovudine metabolite, 3’-amino-3’-284 
deoxythymidine, which shows seven-fold higher toxicity in bone marrow cells compared to 285 
the parent drug.76 286 
 287 
  
The increased exposure and decreased clearance of zidovudine suggests that atovaquone 288 
is inhibiting the glucuronidation of zidovudine. The primary enzyme involved in zidovudine 289 
glucuronidation is uridine 5'-diphospho-glucuronosyltransferase (UGT) 2B7.77 Therefore, 290 
clearance of UGT2B7 substrates, such as the anti-HIV drug efavirenz, may also be 291 
influenced by atovaquone and further investigations are warranted in this area.77 292 
 293 
Atovaquone did not alter the exposure of the anti-HIV protease inhibitor drug indinavir in 294 
healthy volunteers.78 Indinavir is a substrate of the drug efflux transporter, ABCB1, and the 295 
absence of any effect of atovaquone on indinavir pharmacokinetics suggests that 296 
atovaquone is not altering the activity of ABCB1, although this has not been confirmed.79 297 
 298 
Safety and Toxicology  299 
Atovaquone has been found to be generally well tolerated and causes few side effects.  300 
Adverse events are generally mild and include rash, fever, vomiting, diarrhoea, abdominal 301 
pain and headache. Indeed, overdoses as large as 31,500 mg have been reported causing 302 
little or no symptomatology.80 303 
 304 
Conclusion  305 
Despite the extensive use of Atovaquone-Proguanil, there remains a considerable 306 
knowledge gap concerning its pharmacology. The rollout of generics following the expiry of 307 
the patent will undoubtedly see an increase in Atovaquone-Proguanil usage that will be 308 
closely followed by an increase in the treatment failures. Clearly, if the community is to 309 
manage this issue and develop improved derivatives, more effort needs to be placed into 310 
understanding the PK-PD mechanisms underpinning Atovaquone-Proguanil treatment 311 
failure. 312 
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Figure 1.  Historical development of atovaquone and its PK properties (m-measured, p-521 
predicted). 522 
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Figure 2: Synthetic routes used to synthesise atovaquone 535 
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Figure 3: Panel (a). Cartoon representation of the yeast cytochrome bc1 complex 545 
(3CX5.PDB, with atovaquone modelled at the Qo site (boxed area).81 The bc1 complex is a 546 
structural and functional homodimer with a molecular mass of approximately 480 kDa, 547 
consisting of 10 discrete subunits per monomer in yeast and P. falciparum. The electron-548 
transferring catalytic unit of one monomer is highlighted; cytochrome b is represented in 549 
orange, cytochrome c1 in blue and the Rieske iron-sulpur protein (ISP) in green. Haem 550 
groups (cyt b and cyt c1) are shown in red. The remaining subunits of the complex are 551 
rendered in grey. Panel (b) Molecular model of atovaquone (ATO) bound to the Qo site of 552 
the bc1 complex. Subunits are coloured as in panel (a). Atovaquone was modelled into the 553 
Qo site of cytochrome b as described by Fisher N et al.46 Hydrogen-bonding interactions 554 
between the naphthoquinone headgroup of atovaquone and sidechains of Glu-272 (cyt b) 555 
and His-181 (ISP) are indicated by yellow lines. The positions of haem bl (cyt b) and the ISP 556 
[2Fe2S] cluster are also shown. 557 
 558 
  
 559 
Figure 4.  Atovaquone plasma concentration-time profile after single dose of Malarone in 13 560 
healthy individuals. Used with permission from the study by Thaper et al.51 561 
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